Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial

Journal of Affective Disorders

Volumn 101, Issue 1-3, 2007, Pages 275-281

  McElroy, Susan L ^a   Suppes, Trisha ^b   Frye, Mark A ^c   Altshuler, Lori L ^c   Stanford, Kevin ^a   Martens, Brian ^a   Leverich, Gabriele S ^d   Post, Robert M ^d   Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Akathisia; Aripiprazole; Bipolar; Depression

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ACTIVATION SYMPTOMS; ADULT; AKATHISIA; ANALYSIS OF VARIANCE; ANXIETY; APPETITE; ARTICLE; BIPOLAR DEPRESSION; BLURRED VISION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE MODIFIED FOR BIPOLAR ILLNESS; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MANIA; MENTAL CONCENTRATION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARANOIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLURRED SPEECH; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TREMOR; URINARY FREQUENCY; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PILOT PROJECTS; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES;

EID: 34247163368     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2006.11.025     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition (1994), American Psychiatric Association, Washington, DC
2. Aprison M.H., Takahashi R., and Tachiki K. Hypersensitive serotonergic receptors involved in clinical depression - a theory. In: Haber B., and Aprison M.H. (Eds). Neuropharmacology and Behavior (1978), Plenum, New York, NY 23-48
3. Barbee J.G., Conrad E.J., and Jamhour N.J. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16 (2004) 189-194
4. Barnes T.R. A rating scale for drug induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
5. Barzman D.H., DelBello M., Kowatch R.A., Gernert B., Fleck D.E., Pathak S., Rappaport K., Delgado S.V., Campbell P., and Strawkowski S.M. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J. Child Adolesc. Psychopharmacol. 14 (2004) 593-600
6. Brune M. The incidence of akathisia in bipolar affective disorder treated with neuroleptics - a preliminary report. J. Affect. Disord. 53 (1999) 175-177
7. Calabrese J.R., Elhaj O., Gajwani P., and Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J. Clin. Psychiatry 66 Suppl. 5 (2005) 26-33
8. Calabrese J.R., Keck Jr. P.E., MacFadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 (2005) 1351-1360
9. Fagiolini A., Frank E., Scott J.A., Turkin S., and Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 7 (2005) 424-430
10. First M.B., Spitzer R.L., Gibbon M., et al. Structured Clinical Interview for DSM-IV Axis I disorders (Research Version, 2/96 Final) (1996), Biometrics Research Department, New York State Psychiatric Institute, New York, NY
11. Fleischhacker W.W. Aripiprazole. Expert. Opin. Pharmacother. 6 (2005) 2091-2101
12. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety 29 (2006) 303-319
13. Ghaemi S.N., Hsu D.J., Rosenquist K.J., Pardo T.B., and Goodwin F.K. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 209-213
14. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 161 (2004) 564-566
15. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338 (1976), US Department of Health, Education, and Welfare, Washington, DC 534-537
16. Hellerstein D.J. Aripiprazole as an adjunctive treatment for refractory major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 1347-1348
17. Keck Jr. P.E., and McElroy S.L. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J. Clin. Psychiatry 64 (2003) 1426-1435
18. Keck Jr. P.E., and McElroy S.L. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin. Investig. Drugs 12 (2003) 655-662
19. Keck Jr. P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. J. Clin. Psychiatry 160 (2003) 1651-1658
20. Keck Jr. P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., Marcus R.N., and Sanchez R. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar disorder. J. Clin. Psychiatry 67 (2006) 626-637
21. Ketter T.A., Wang P.W., Chandler R.A., Culver J.L., and Alarcon A.M. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann. Clin. Psychiatry 18 (2006) 169-172
22. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., and Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 (2003) 123-136
23. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
24. Nemeroff C.B., Lieberman J.A., Weider P.J., and Harvey P.D. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 10 Suppl (2005) 1-20
25. Rachid F., Bertschy G., Bondolfi G., and Aubry J.-M. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J. Clin. Psychiatry 65 (2004) 1537-1545
26. Sachs G.S., Sanchez R., Marcus R.N., Stock E., McQuade R., Carson W., Abou-Gharbia N., Impellizzeri C., Kaplita S., Rollin L., and Iwamoto T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20 (2006) 536-546
27. Seemüller F., Forsthoff A., Dittman S., Born C., Bernhard B., Severus W.E., and Grunze H. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin. Drug Saf. 4 (2005) 849-868
28. Spearing M.K., Post R.M., Leverich G.A., Brandt D., and Nolen W. Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73 (1997) 159-171
29. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (1970) S11-S19
30. Tohen M., Vieta E., Calabrese J., Setter T.A., Sachs G., Borden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 (2003) 1079-1088
31. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Swanink R., Iwamoto T., and on behalf of the Aripiprazole. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br. J. Psychiatry 187 (2005) 235-242
32. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology. The Fourth Generation of Progress (1995), Raven Press, New York, NY 921-931
33. Worthington III J.J., Kinrys G., Wygant L.E., and Pollack M.H. Aripiprazole as an augmenter of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 20 (2005) 9-11
34. Yatham L.N. Atypical antipsychotics for bipolar disorder. Psychiatr. Clin. North Am. 28 (2005) 325-347
35. Yatham L.N., Goldstein J.M., Vieta E., Borden C.L., Grunze H., Post R.M., Suppes T., and Calabrese J.R. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 66 Suppl. 5 (2005) 40-48
36. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435
37. Zarate Jr. C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., Charney D.S., and Manji H.K. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 56 (2004) 54-60